Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More
Cardiovascular Disease
ILUMIEN IV: OCT-Guided vs. Angio-Guided PCI
Unveiling the ILUMIEN IV Trial: A New Era of Percutaneous Coronary Intervention The ILUMIEN IV: OPTIMAL PC Trial, conducted in 2023, is a landmark study that compares the efficacy of Optical Coherence Tomography (OCT)-guided coronary stent implantation to the traditional … Read More
BYPASS-CTCA: CT Angio before Cath in Patients with CABG
The BYPASS-CTCA Trial: Enhancing Cardiac Procedures with Pre-Operative CT Scans In 2023, the BYPASS-CTCA Trial set out to redefine the pre-operative protocol for patients with a history of coronary artery bypass grafting (CABG). This open-label randomized controlled trial posed a … Read More
ARTESIA Trial: Apixaban for Subclinical AFib
ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More
DAPA-MI Trial: Dapagliflozin in MI
DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
ADVENT Trial: Pulse Field Ablation for AFib
The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More
Target-HTN trial: Lorundrostat in Hypertension
The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More
OCTOBER Trial: OCT in Complex PCI
The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More
LODESTAR Trial: Statin and CAD
The LODESTAR trial, as featured in JAMA in 2023, was a randomized, multicenter, noninferiority trial focusing on coronary artery disease (CAD) treatment strategies. The objective was to assess whether a treat-to-target strategy for low-density lipoprotein cholesterol (LDL-C) is noninferior to … Read More